Wosulin-30/70 Special Precautions

Never share a Biphasic Isophane Insulin (rDNA Origin) (Wosulin-30/70) or syringe between patients, even if the needle is changed.
Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen: Make changes to a patient's insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of blood glucose monitoring.
Hypoglycemia: May be life-threatening. Monitor blood glucose and increase monitoring frequency with changes to insulin dosage, use of glucose lowering medications, meal pattern, physical activity; in patients with renal or hepatic impairment; and in patients with hypoglycemia unawareness.
Hypersensitivity Reactions: May be life-threatening. Discontinue Biphasic Isophane Insulin (rDNA Origin) (Wosulin-30/70), monitor and treat if indicated.
Hypokalemia: May be life-threatening. Monitor potassium levels in patients at risk of hypokalemia and treat if indicated.
Fluid Retention and Heart Failure with Concomitant Use of Thiazolidinediones (TZDs): Observe for signs and symptoms of heart failure; consider dosage reduction or discontinuation if heart failure occurs.
Switching to different type of insulin: If the patient is switching to another type of insulin, it should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (rapid acting insulin, intermediate acting insulin, long acting insulin, etc.), species (animal, insulin human analog) and/or method of manufacture (recombinant versus animal source insulin) may result in the need for a change in dose. Patients switching to Biphasic Isophane insulin human suspension may require a change in dosage from that used with their usual insulin.
Laboratory Tests: As with all insulins, the therapeutic response to human insulin should be monitored by periodic blood glucose tests. Periodic measurement of glycosylated hemoglobin is recommended for the monitoring of long-term glycemic control.
Renal Impairment: The requirements for insulin may be reduced in patients with renal impairment.
Hepatic Impairment: Although impaired hepatic function does not affect the absorption or disposition of Biphasic Isophane Insulin, careful glucose monitoring and dose adjustments of insulin may be necessary.
Effects on the ability to drive and use machine: The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. This may constitute a risk in situations where those abilities are of special importance (e.g. driving a car or operating machinery). The patient is therefore advised to avoid driving during hypoglycemia. This is particularly significant in patients who have reduced awareness of the warning signs of hypoglycemia or have frequent episodes of hypoglycemia.